Figure 3.

CCL2 is necessary for the recruitment of monocytes to MSU + Msmeg-treated dLNs and tumors. (A) Expression of CCR2 on monocytes (CD11b⁺Ly6B⁺Ly6C⁺CD11c⁻), moDCs (CD11c⁺MHCII⁺Ly6B⁺Ly6C⁺), and other DCs (CD11c⁺MHCII⁺Ly6B⁻Ly6C⁻) in dLNs of mice treated with MSU + Msmeg once 45 h earlier. (B) Frequency of CCR2⁺ monocytes in blood 15 h after MSU + Msmeg treatment. (C,D) Mice bearing palpable B16.OVA tumors were treated with anti-CCL2 or control antibody. About 2 h later, mice received 2 million purified CD45.1⁺ naive monocytes and were treated with MSU + Msmeg. The recruitment of transferred (CD45.1⁺) or host (CD45.2⁺) monocytes (Ly6B⁺Ly6C⁺CD11c⁻) to LN (C) and tumors (D) was examined 18 h later. Data are pooled from two independent experiments each with 3–5 mice/group. All graphs show mean + SEM. Statistical analyses used a Student’s t-test (B) or a Kruskal–Wallis with Dunn’s post-test (C,D).